CA2289760A1 - Vaccin dirige contre les noyaux de lipopolysaccharides - Google Patents

Vaccin dirige contre les noyaux de lipopolysaccharides Download PDF

Info

Publication number
CA2289760A1
CA2289760A1 CA002289760A CA2289760A CA2289760A1 CA 2289760 A1 CA2289760 A1 CA 2289760A1 CA 002289760 A CA002289760 A CA 002289760A CA 2289760 A CA2289760 A CA 2289760A CA 2289760 A1 CA2289760 A1 CA 2289760A1
Authority
CA
Canada
Prior art keywords
lps
antigen
bacterium
core
coli
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002289760A
Other languages
English (en)
Inventor
Thomas James Mcintosh
David Scott Snyder
Ian Raymond Poxton
Elliott Bennett-Guerrero
George Robin Barclay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDICAL DEFENSE TECHNOLOGIES LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2289760A1 publication Critical patent/CA2289760A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Selon cette invention, on incorpore à un vaccin se présentant généralement sous forme de liposomes, des lipopolysaccharides (LPS) à noyau complet (dépourvus de chaînes latérales de O-polysaccharide) provenant de bactéries Gram négatif. Le noyau complet de E.coli K12 s'avère particulièrement utile. Lorsqu'on l'administre à un mammifère, ce vaccin stimule la synthèse d'anticorps qui assurent une protection croisée contre les formes lisses et rugueuses de LPS, à partir d'au moins deux souches bactériennes Gram négatif dotées de structures de noyaux différentes.
CA002289760A 1997-05-16 1998-05-15 Vaccin dirige contre les noyaux de lipopolysaccharides Abandoned CA2289760A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4668097P 1997-05-16 1997-05-16
US60/046,680 1997-05-16
PCT/US1998/009988 WO1998051217A1 (fr) 1997-05-16 1998-05-15 Vaccin dirige contre les noyaux de lipopolysaccharides

Publications (1)

Publication Number Publication Date
CA2289760A1 true CA2289760A1 (fr) 1998-11-19

Family

ID=21944797

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002289760A Abandoned CA2289760A1 (fr) 1997-05-16 1998-05-15 Vaccin dirige contre les noyaux de lipopolysaccharides

Country Status (5)

Country Link
EP (1) EP1011440A4 (fr)
JP (1) JP2001527562A (fr)
AU (1) AU7491298A (fr)
CA (1) CA2289760A1 (fr)
WO (1) WO1998051217A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20085812A0 (fi) * 2008-09-01 2008-09-01 Esa-Matti Lilius Karkea LPS immunostimulanttina vesiviljelyssä
AU2012269740A1 (en) * 2011-06-17 2013-01-31 Immuron Limited Method and composition for treatment or inhibition of mucositis associated with chemotherapy or radiation damage
CN108431049B (zh) * 2015-12-22 2021-07-27 葛兰素史密丝克莱恩生物有限公司 Lps提取工艺
FR3072880A1 (fr) * 2017-10-30 2019-05-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Formulation liposomale et son utilisation en therapie anti-tumorale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
ES2070266T3 (es) * 1989-08-18 1995-06-01 Akzo Nobel Nv Vacuna contra la infeccion por escherichia coli.
ATE173634T1 (de) * 1994-04-20 1998-12-15 Us Army Impfstoff gegen gram-negative bakterielle infektionen
US5730989A (en) * 1995-02-16 1998-03-24 Novavax, Inc. Oral vaccine against gram negative bacterial infection

Also Published As

Publication number Publication date
EP1011440A4 (fr) 2003-08-06
AU7491298A (en) 1998-12-08
WO1998051217A1 (fr) 1998-11-19
EP1011440A1 (fr) 2000-06-28
JP2001527562A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
AU631377B2 (en) Affinity associated vaccine
US5026557A (en) Adjuvant composition
JP2005514388A (ja) グラム陰性菌由来の外膜小胞およびワクチンとしての使用
AU2001256461B2 (en) Immunotherapeutic methods and compositions
Lee et al. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy
EP0356340B1 (fr) Vaccin à affinité associée
US6749831B1 (en) Vaccine against lipopolysaccharide core
US5013555A (en) Agent for desensitizing man and/or animals against an allergen
Fukutome et al. Intestinal mucosal immune response in chickens following intraocular immunization with liposome-associated Salmonella enterica serovar enteritidis antigen
Sheikh et al. Generation of antigen specific CD8+ cytotoxic T cells following immunization with soluble protein formulated with novel glycoside adjuvants
US5897873A (en) Affinity associated vaccine
US5888519A (en) Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
Alfandari et al. Transforming parasites into their own foes: parasitic extracellular vesicles as a vaccine platform
Childers et al. Mucosal and systemic responses to an oral liposome-Streptococcus mutans carbohydrate vaccine in humans.
CA2289760A1 (fr) Vaccin dirige contre les noyaux de lipopolysaccharides
Nakhla et al. Serum anti-LPS antibody production by rainbow trout (Oncorhynchus mykiss) in response to the administration of free and liposomally-incorporated LPS fromAeromonas salmonicida
Aref et al. Novel heat stable enterotoxin (STa) immunogen based on cationic nanoliposomes: preparation, characterization and immunization
Lipld Rough LPs.
AU667028B2 (en) Lipid A composition as immunogenic agents to prevent or treat gram-negative bacterial infections
Agarwal et al. Effect of selected lipids and surfactants on immunogenicity of several bacterial antigens
WO1990001947A1 (fr) Vaccin a affinite associee
RU2683027C2 (ru) Поливалентная иммунизирующая и/или терапевтическая композиция для применения при бактериальных инфекциях или пищевом отравлении, в частности сальмонеллёзе, способ получения этой композиции, её применение и вакцина, содержащая эту композицию
AU1747097A (en) Compositions and methods for administering borrelia burgdorferi antigens
CA2761917A1 (fr) Procede de detoxification du lipopolysaccharide (lps) ou du lipide a des bacteries a gram-negatif
CA1334165C (fr) Vaccin avec antigenes associes par affinite

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead